Who are Olimel N12's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fat emulsion with MCT and LCT, SmofKabiven.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olimel-n12.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Olimel N12 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olimel N12 (Olimel N12) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parenteral nutrition emulsion. Area: Nutrition support / Critical care.

marketed Parenteral nutrition emulsion Nutrition support / Critical care Small molecule Live · refreshed every 30 min

Target snapshot

Olimel N12 (Olimel N12) — Erasmus Medical Center. Olimel N12 is a parenteral nutrition emulsion that provides balanced macronutrients (amino acids, glucose, and lipids) to support metabolic needs in patients unable to eat orally.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Olimel N12 TARGET	Olimel N12	Erasmus Medical Center	marketed	Parenteral nutrition emulsion
Fat emulsion with MCT and LCT	Fat emulsion with MCT and LCT	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	marketed	Parenteral nutrition emulsion
SmofKabiven	SmofKabiven	JW Life Science	marketed	Parenteral nutrition emulsion

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parenteral nutrition emulsion class)

Erasmus Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class
JW Life Science · 1 drug in this class
RWTH Aachen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olimel N12 — Competitive Intelligence Brief. https://druglandscape.com/ci/olimel-n12. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing